Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
INFEX Therapeutics logo — Vital new drugs for pandemic infections

INFEX Therapeutics

Vital new drugs for pandemic infections

Founded 2016 United Kingdom Alderley Edge, United Kingdom 22 employees Angel Total: $2.30M Biotechnology, Pharmaceutical

General Information

Company Name INFEX Therapeutics
Founded Year 2016
Location United Kingdom Alderley Edge, United Kingdom
Employees 22
Industries Biotechnology, Pharmaceutical
Funding Stage Angel
Social

BounceWatch is an independent company data service, not affiliated with INFEX Therapeutics. To contact INFEX Therapeutics, visit infextx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does INFEX Therapeutics compare?

A PDF of INFEX Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting INFEX Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About INFEX Therapeutics

INFEX Therapeutics, founded in 2016 and headquartered in the United Kingdom, is focused on acquiring, developing, and licensing innovative drugs to address pandemic infections. With a slogan of "Vital new drugs for pandemic infections," the company's mission is to meet the rising burden of critical priority infectious diseases. INFEX Therapeutics, based at Alderley Park in the North West of England, is dedicated to developing a broader portfolio of new therapies to address unmet patient needs. The company recently secured a significant £2.30M Angel Round investment on 25 March 2019, with support from notable investors including LifeArc, GM&C Life Sciences Fund, and SciTech. INFEX Therapeutics is poised to bring a new portfolio of drugs into clinical trials, aiming to provide effective treatment for patients suffering from life-threatening infections.

Business keywords: pharmaceuticals, infectious diseases, medication development, clinical trials, antibiotics, innovation, post-processing solutions, revenue enhancement, leadership, 3D printing, polymer technology, commercial partnerships

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Angel Round £2.30M 3
LifeArc GM&C Life Sciences Fund SciTech
LifeArc, GM&C Life Sciences Fund +1
25 Mar 2019
Venture Round Undisclosed 2
Catapult Venture Managers GM&C Life Sciences Fund
Catapult Venture Managers, GM&C Life Sciences Fund
01 Jan 2017

INFEX Therapeutics Alternatives & Competitors

View All Alternatives
INFEX Therapeutics vs
Melinta Therapeutics
Melinta Therapeutics United States

Unparalleled in Passion & Purpose

Post-IPO Equity
156 employees
Biotechnology, Health Care
INFEX Therapeutics vs
Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd Australia

Recce Pharmaceuticals (ASX:RCE) is pioneering a New Class of Synthetic Anti-Infectives to combat AMR...

Grant
19 employees
Biotechnology, Pharmaceutical
INFEX Therapeutics vs
Xcene Research
Xcene Research Nigeria

Finding Innovative Global Health Solutions For Today and Tomorrow Through Clinical Research. # Organ...

110 employees
Biotechnology, Health Care
View all alternatives

FAQ About INFEX Therapeutics

Vital new drugs for pandemic infections
INFEX Therapeutics was founded in 2016.
INFEX Therapeutics is headquartered in Alderley Edge, United Kingdom.
INFEX Therapeutics operates in Biotechnology and Pharmaceutical. Its work centres on pharmaceuticals, infectious diseases, medication development and clinical trials.
INFEX Therapeutics has approximately 22 employees.
INFEX Therapeutics has completed 2 funding rounds, raising a total of $2.30M. The latest funding stage is Angel.
Top alternatives and competitors to INFEX Therapeutics include Melinta Therapeutics, Recce Pharmaceuticals Ltd, Xcene Research, Cantex Pharmaceuticals, Inc., Senolytx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
INFEX Therapeutics and Melinta Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for INFEX Therapeutics, https://bouncewatch.com/company/amr-centre, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes